Analyses suggest that ribociclib improves progression-free survival across most intrinsic subtypes of HR-positive/HER2-negative disease, and overall survival benefits with the drug are still evident at about 4.5 years of follow-up.
Results from the RxPONDER trial suggest some breast cancer patients can forgo chemotherapy – specifically, postmenopausal women with hormone receptor–positive, HER2-negative breast cancer who have one to three involved nodes and a 21-gene recurrence score of 25 or less.
Two trials suggest we must be somewhat concerned about the chemotherapy partner used with an immune checkpoint inhibitor in patients with advanced triple-negative breast cancer (TNBC) expressing programmed death–ligand 1 (PD-L1).
In 2016, an opinion piece published in the journal Nature threw cold water on the concept of precision oncology — tailoring the treatment of individual patients to the genetic characteristics of their tumors.
Combination therapy with a cyclin-dependent kinase (CDK) 4/6 inhibitor and an aromatase inhibitor (AI) has the same good efficacy but greater toxicity in women with hormone receptor (HR)–positive, HER2-negative advanced breast cancer who are aged 75 years or older, a pooled analysis of randomized controlled trials concluded.